Agenus gets Sharp on board
This article was originally published in Scrip
Oncology biotech Agenus has appointed Shalini Sharp to its board of directors effective 11 May 2012. Ms Sharp has served as Agenus' vice-president and CFO since 2006, but will step down as CFO when she joins the board. She joined Agenus in 2003, having previously served at Elan Pharmaceuticals. From 11 May, Christine Klaskin, vice-president of finance, will be responsible for the company's day-to-day financial operations, serving as principal accounting officer and principal financial officer.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.